Abstract | OBJECTIVE:
Chagas' disease has spread throughout Latin America because of the high rate of migration among these countries. Approximately 30% of Chagas' patients will develop cardiomyopathy, and 10% of these will develop severe cardiac damage leading to heart failure. Beta-blockade improves symptoms and survival in heart failure patients; however, its efficacy has not been well established in Chagas' disease. We evaluated the role of carvedilol in cardiac remodeling and mortality in a Chagas' cardiomyopathy animal model. METHODS: RESULTS: The left ventricular diastolic diameter did not change between groups, although it was slightly larger in infected groups, as was left ventricular systolic diameter. Fractional shortening also did not change between groups, although it was slightly lower in infected groups. Collagen accumulation in the interstitial myocardial space was significantly higher in infected groups and was not attenuated by carvedilol. The same response was observed in the perivascular space. The survival curve showed significantly better survival in the control group compared with the infected groups; but no benefit of carvedilol was observed during the study. However, in the acute phase (up to 100 days of infection), carvedilol did reduce mortality. CONCLUSION:
Carvedilol did not attenuate cardiac remodeling or mortality in this model of Chagas' cardiomyopathy. The treatment did improve survival in the acute phase of the disease.
|
Authors | Walace de Souza Pimentel, Felix José Alvarez Ramires, Barbara Maria Lanni, Vera Maria Cury Salemi, Angelina Morand Bianchi Bilate, Edecio Cunha-Neto, Adriana Morgan de Oliveira, Fábio Fernandes, Charles Mady |
Journal | Clinics (Sao Paulo, Brazil)
(Clinics (Sao Paulo))
Vol. 67
Issue 9
Pg. 1063-9
(Sep 2012)
ISSN: 1980-5322 [Electronic] United States |
PMID | 23018305
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic beta-Antagonists
- Carbazoles
- Propanolamines
- Carvedilol
- Collagen
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Animals
- Carbazoles
(therapeutic use)
- Carvedilol
- Chagas Cardiomyopathy
(drug therapy, mortality, pathology)
- Collagen
(analysis)
- Cricetinae
- Disease Models, Animal
- Echocardiography
- Female
- Heart Rate
(drug effects)
- Heart Ventricles
(physiopathology)
- Kaplan-Meier Estimate
- Mesocricetus
- Propanolamines
(therapeutic use)
- Survival Rate
- Time Factors
- Treatment Outcome
- Ventricular Remodeling
(drug effects)
|